<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04588337</url>
  </required_header>
  <id_info>
    <org_study_id>y2020-022</org_study_id>
    <nct_id>NCT04588337</nct_id>
  </id_info>
  <brief_title>INtravenous TNK for Acute isChemicsTroke in China</brief_title>
  <official_title>INtravenous TNK for Acute isChemicsTroke in China (INTACT-China): a Prospective, Multi-center, Registry Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Hospital of Shenyang Military Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General Hospital of Shenyang Military Region</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute ischemic stroke is the most common type of stroke, accounting for about 60%-80% of all&#xD;
      stroke, with high incidence, high mortality, high disability rate, has become the first cause&#xD;
      of death in China. At present, only ultra-early thrombolytic therapy, endovascular therapy&#xD;
      and antiplatelet therapy have obtained evidence-based medical evidence in ischemic stroke&#xD;
      treatment, but only thrombolytic therapy and endovascular therapy can improve the good&#xD;
      prognosis of patients. Intravenous thrombolytic therapy within 4.5 hours after the onset of&#xD;
      ischemic stroke symptoms has been shown to be effective, which is recommended in the&#xD;
      guidelines.&#xD;
&#xD;
      In most countries, alteplase (R-tPA) is the only drug approved for the treatment of acute&#xD;
      ischemic stroke. Recombinant human TNK tissue-type plasminogen activator (rhTNK-tPA) is a&#xD;
      modified recombinant tissue-type plasminogen activator, with no procoagulant effect and a&#xD;
      longer half life. In recent years, there are some studies on the comparison of therapeutic&#xD;
      effects of TNK-tPA and RT-PA in patients with acute ischemic stroke, and TNK shows promising&#xD;
      especially for large artery occlussion. At present, there are few reports on the application&#xD;
      of rhTNK-tPA in Chinese stroke patients.&#xD;
&#xD;
      The aim of this study is to evaluate the efficacy and safety of rhTNK-tPA in Chinese patients&#xD;
      with ischemic stroke in a prospective, multicenter registration study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 10, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of excellent prognosis (mRS 0-1)</measure>
    <time_frame>90 ± 7 days</time_frame>
    <description>The proportion of excellent prognosis (mRS 0-1) after thrombolysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the proportion of good prognosis (mRS 0-2)</measure>
    <time_frame>90 ± 7 days</time_frame>
    <description>The proportion of good prognosis (mRS 0-2) after thrombolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of stroke deterioration after thrombolysis</measure>
    <time_frame>within 1 week</time_frame>
    <description>NIHSS score increased by more than 2, excluding cerebral hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence of stroke recurrence and other vascular events</measure>
    <time_frame>within 90 ± 7 days</time_frame>
    <description>the incidence of stroke recurrence and other vascular events within 90 ± 7 days after thrombolysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptomatic intracerebral hemorrhage</measure>
    <time_frame>within 36 hours</time_frame>
    <description>any evidence of bleeding on the head CT scan associated with clinically significant neurological deterioration (NIHSS score ≥4 points increase)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Stroke, Ischemic</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhTNK-tPA</intervention_name>
    <description>Thrombolysis</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        acute ischemic stroke patients who is eligible for intravenous thrombolysis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 ;&#xD;
&#xD;
          2. The time from onset to treatment was less than 4.5 hours;&#xD;
&#xD;
          3. Ischemic stroke confirmed by head CT or MRI;&#xD;
&#xD;
          4. There are measurable neurological deficits;&#xD;
&#xD;
          5. First onset or previous onset without obvious sequelae (Mrs ≤1 score) ;&#xD;
&#xD;
          6. signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe neurologic deficits before onset (mRS ≥2) ;&#xD;
&#xD;
          2. Significant head trauma or stroke in the last 3 months;&#xD;
&#xD;
          3. Subarachnoid hemorrhage;&#xD;
&#xD;
          4. A history of intracranial hemorrhage or head injury or acute stroke within 3 months;&#xD;
&#xD;
          5. Intracranial tumors, arteriovenous malformations or aneurysms;&#xD;
&#xD;
          6. Intracranial or spinal cord surgery within 3 months;&#xD;
&#xD;
          7. Non-compressible arterial puncture within 7 days;&#xD;
&#xD;
          8. Gastrointestinal or urinary tract hemorrhage within last 21 days;&#xD;
&#xD;
          9. Major surgery within 1 month;&#xD;
&#xD;
         10. Thrombocytopenia (platelet count &lt;10×109/L);&#xD;
&#xD;
         11. Use of heparin or oral anticoagulation therapy within 48 hours;&#xD;
&#xD;
         12. Use of warfarin with an international normalised ratio &gt;1.7 or PT &gt;15 s;&#xD;
&#xD;
         13. Uncontrolled hypertension (SYSTOLIC &gt;180 mmHg OR DIASTOLIC&gt;110 mmHg) ;&#xD;
&#xD;
         14. The Blood Glucose concentration &lt;50 mg/dl (2.7 mmol/L);&#xD;
&#xD;
         15. Severe systemic disease with poor life expectancy (&lt;3 months); ;&#xD;
&#xD;
         16. Allergic to research drug;&#xD;
&#xD;
         17. Within 3 months or participating in other clinical trials;&#xD;
&#xD;
         18. Other conditions due to which investigators consider study participation&#xD;
             inappropriate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 3, 2020</study_first_submitted>
  <study_first_submitted_qc>October 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Hospital of Shenyang Military Region</investigator_affiliation>
    <investigator_full_name>Hui-Sheng Chen</investigator_full_name>
    <investigator_title>Head of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

